Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- GENERIC NEWS IN BRIEF
January 8, 2007
- Teijin to Invest in New Businesses Including Healthcare
January 8, 2007
- MEDICAL DEVICE NEWS IN BRIEF
January 8, 2007
- BUSINESS NEWS IN BRIEF
January 8, 2007
- Hospitals to Demand that Insurers Pay Unpaid Copayments
January 8, 2007
- JPLA Seminae
January 8, 2007
- J&J Extends Its SOHO Day System to Include Employees with School Children
January 8, 2007
- UtoBrain Seminae
January 8, 2007
- No NHI Price Revision in FY2007: Chuikyo
January 8, 2007
- Gov't Approves 2.5% Budget Increase for Korosho
January 8, 2007
- Council to Begin Drafting Innovation 25 Strategy
January 8, 2007
- REGULATORY NEWS IN BRIEF
January 8, 2007
- PMDA to Increase Transparency on Posting of Ex-Employees of Companies
December 25, 2006
- BUSINESS NEWS IN BRIEF
December 25, 2006
- Nippon Keidanren Leaders Exchange Opinions with Korosho Leaders
December 25, 2006
- Novartis Highlights Strong R&D Pipeline
December 25, 2006
- Korosho Hears from 5 Parties to Promptly Bring New Drugs to Patients
December 25, 2006
- R&D NEWS IN BRIEF
December 25, 2006
- System That Fairly Awards Innovation Needed: WG for New Industry Vision
December 25, 2006
- Risk Classification for OTC Drugs Nearly Complete: PFSB
December 25, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…